Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease
Open Forum Infectious Diseases · 30.06.2025 · 12 (7)
DOI: 10.1093/ofid/ofaf369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 02.07.2025. Verfasst von Wei Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Hospital Development Center, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Background
We aimed to investigate the prevalence of liver fibrosis and identify the associated risk factors among people with HIV (PWH) and metabolic dysfunction–associated steatotic liver disease (MASLD).
Methods
Abdominal ultrasonography and transient elastography were performed to assess liver fibrosis and steatosis. Lean MASLD was defined as MASLD occurring in PWH with a body mass index (BMI) < 24 kg/m2. A cutoff of liver stiffness measurement ≥ 7.1 kPa was set for significant liver fibrosis. The prevalence, correlation factors, and risk factors were evaluated.
Results
Among 361 PWH, 250 (69.25%) had a BMI < 24 kg/m2, and 141 (39.06%) were diagnosed with MASLD. The 141 PWH with MASLD were classified as 2 groups based on BMI: 58 (41.13%) as lean MASLD and 83 (58.87%) as overweight MASLD. Significant fibrosis was observed in 121 of the 361 PWH, including 75 of the 141 with MASLD, 28 of the 58 with lean MASLD, and 47 of the 83 with overweight MASLD. Among PWH with MASLD, independent risk factors for significant liver fibrosis included higher alanine aminotransferase levels and the presence of type 2 diabetes. Among PWH with lean MASLD, independent risk factors for significant liver fibrosis included elevated aspartate aminotransferase levels and the administration of non-nucleoside reverse transcriptase inhibitors.
Conclusions
Significant liver fibrosis is highly prevalent among PWH and MASLD. Multiple risk factors are associated with significant liver fibrosis among PWH. These findings underscore the importance of early identification and management of liver fibrosis in PWH. Clinical Trials Registration NCT04215926.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Förderung
- Shanghai Hospital Development Center
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Xu, W., Liu, D., Zhang, R., Chen, J., & Shen, Y. (2025). Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease. Open Forum Infectious Diseases, 12(7). https://doi.org/10.1093/ofid/ofaf369
Vancouver
Xu W, Liu D, Zhang R, Chen J, Shen Y. Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease. Open Forum Infectious Diseases. 2025;12(7). doi:10.1093/ofid/ofaf369
BibTeX
@article{Xu2025,
author = {Xu, Wei and Liu, Danping and Zhang, Renfang and Chen, Jun and Shen, Yinzhong},
title = {Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {7},
doi = {10.1093/ofid/ofaf369}
}
EUVIMED